A recent post hoc analysis of the results from the COMPARZ clinical trial, which compared first-line treatment with pazopanib versus sunitinib for metastatic renal cell carcinoma (RCC), was published in Clinical Genitourinary Cancer last February 2020.
During the COMPARZ study, pazopanib and sunitinib (VEGF-TKI targeted therapy) had similar efficacy. However, this analysis showed that the patients who had a reduction in their dose of VEGF-TKI targeted therapy due to treatment-related adverse events had better clinical outcomes (progression-free survival, overall survival, and objective response rate) than those who did not have dose reductions.
In addition, patients who had a dose reduction because of adverse events continued with their treatment for longer, received a higher cumulative dose of VEGF-TKI targeted therapy, and ultimately had more side effects than patients who did not have a reduction in dose.
In conclusion, these findings are reassuring since they show that a reduction in dose because of toxicity does not compromise the efficacy of VEGF-TKI targeted therapy. In addition, this study highlights the importance of maintaining the balance between the effects of the cancer and treatment-related adverse events to improve the overall outcomes of patients, and supports the suggestion of a link between adverse events and clinical outcomes from VEGF-TKI targeted therapies.